ABSTRACT-The effects of toborinone ([(±)-6-[3-(3,4-dimethoxybenzylamino)-2-hydroxypropoxy]-2(1H)-quinolinone], OPC-18790), milrinone and E-4031 (1-(2-(6-methyl-2-pyridil)-1-ethyl)-4-(4-methanesulfonylamino-l-benzoyl)piperidine dihydrochloride) on membrane potential were examined in isolated guinea pig sinoatrial node preparations. Toborinone, a new positive inotropic agent, prolonged cycle length (CL), depolarized maximum diastolic potential (MDP) and decreased maximum upstroke velocity (Vmax) and action potential amplitude (APA). On the other hand, milrinone, a peak III phosphodiesterase (PDE III) inhibitor, increased Vmax and APA and shortened CL and action potential duration. E-4031, an IK blocker, prolonged CL, depolarized MDP and decreased Vmax and APA. These results suggest that toborinone modulates the action potential like an IK blocker rather than a PDE III inhibitor in a sinoatrial node.
Toborinone ([(±)-6-[3-(3,4-dimethoxybenzylamino)-2-hydroxypropoxy]-2(1H)-quinolinone],
known as OPC-18790 in former publications) is a novel positive inotropic agent (1, 2) . This compound has an inhibitory action on the peak III phosphodiesterase (PDE III) of isolated heart in dogs (1) and humans (3) . Thus, the positive inotropic effect produced by toborinone may be related, at least in part, to a subsequent increase in intracellular cyclic AMP (1, 2, 4).
Komas et al. (5) reported that PDE III existed in the sinoatrial node area as well as in ventricular muscle. Since elevation of the intracellular cyclic AMP level in a sinoatrial cell enhances potassium and calcium current, resulting in a positive chronotropic action (6), many PDE III inhibitors have a positive chronotropic effect (7) . On the other hand, toborinone has only small effect on heart rate (1, 4) in spite of its inhibitory action on PDE III. There arises a question about why toborinone has a limited positive chronotropic action although this compound has an inhibitory action on PDE III. Toborinone clearly differs from other PDE III inhibitors in its prolonging effect on action potential duration in isolated papillary muscle (1). Takase et al. (4, 8) reported that toborinone blocked the delayed rectifier potassium current (IK). This action is like that of a class III antiarrhythmic agent such as E-4031 (1-(2-(6-methyl-2-pyridil)-1-ethyl)-4-(4-methanesulfonylaminol -benzoyl)piperidine dihydrochloride) (9) . Because E-4031 prolonged the cycle length in an isolated rabbit sinoatrial node preparation (10), the lack of chronotropic action of toborinone seems to be related to its class III-like action. However, the effect of toborinone on the sinoatrial node has not been examined so far. In this report, we describe how toborinone affects the action potential of a sinoatrial node and compare the effects of toborinone with those of milrinone, a PDE III inhibitor (11) , and E-4031 in a guinea pig sinoatrial node preparation.
Hearts were quickly removed from male Hartley guinea pigs (SLC, Shizuoka) weighing 310-650 g. The perfusion system used in this study was the same as the previously reported one (4). A sinoatrial node was cut from surrounding atrial tissue, pinned to the base of a chamber and perfused with oxygenated warmed (351C) bicarbonate-buffered Tyrode solution (137 mM NaCl, 4.0 mM KCI, 1.8 mM CaC12, 1.0 MM MgC12i 0.4 mM NaH2PO4, 17.9 mM NaHCO3 and 5.6 mM glucose). After suitable amplification with a DC amplifier (DPZ-16F; DIA medical system, Tokyo), the action potential was displayed on an oscilloscope (VC-9; Nihon Kohden, Tokyo). Cycle length (CL) and upstroke velocity (Vmax) were determined from action potential signals by using a tachometer (Model 1321; NEC Medical Systems, Tokyo) and an electronic differentiator (Model 1323, NEC Medical Systems), respectively. These parameters were recorded on a pen recorder (RECTI-HORIZ-8K, NEC Medical Systems). Action potential duration at 50% repolarization level (APD50), action potential amplitude (APA), maximum diastolic potential (MDP) and overshoot potential (OSP) were measured from action potentials recorded on a pen recorder. Actual traces shown in this study were obtained with a signal processor (Model 7T17, NEC Medical Systems).
Toborinone (Otsuka Pharmaceutical Co., Ltd., Tokyo) and milrinone (synthesized in Otsuka Pharmaceutical Co., Ltd.) were dissolved in a lactic acid solution. E-4031 (synthesized in Otsuka Pharmaceutical Co., Ltd.) was dissolved in distilled water. At concentrations of 10-6 and 3 x 10-5 M, toborinone increased cyclic AMP level to exert positive inotropic action as milrinone did in the isolated papillary muscle preparation (4). Thus, these concentrations were used in the present study.
All the results of this study were presented as means±S.E.M.
The values of all groups were compared by ANOVA (repeated measurements) and multiple comparison (Dunnett's method) using a software package (Statistical Analysis System; SAS Institute Japan, Ltd., Tokyo). When P values are 0.05 or less, they are considered to be statistically significant.
The basal values of each parameter were not significantly different among the toborinone-, milrinone-and E-4031-treated groups. All parameters measured were not changed throughout the experiment and lactic acid (1.5 x 10-5 M, vehicle for toborinone and milrinone) did not significantly alter any of the measured parameters. Figure 1 shows the action potential activities of three sinoatrial nodes before and during the administration of 10-6 and 3 x 10-5 M of toborinone (Fig. 1A) and milrinone (Fig. 1B) and 10-8 and 10-7 M of E-4031 (Fig. 1C) . The changes in various electrophysiological parameters induced by these drugs are summarized in Fig. 2 . Toborinone caused concentration-dependent depolarization of MDP, prolongation of CL and a decrease in OSP, APA and Vmax. APD50 was not changed significantly. E-4031, like toborinone, depolarized MDP, prolonged CL and decreased APA and Vmax in a concentration-dependent manner. In contrast to toborinone, E-4031 prolonged APD50 concentration-dependently and hardly changed OSP. Milrinone increased APA and Vmax, shortened CL and APD50 and polarized MDP in a concentrationdependent manner. The elevation of cyclic AMP level in a sinoatrial node cell enhances IK and calcium current (Ica) (6) . The activation of IK and Ica plays an important role in the acceleration of repolarization of action potential and in the increase in Vmax (6, 12) , respectively, in a sinoatrial node cell. Milrinone may raise the cyclic AMP level in a sinoatrial node cell due to its inhibitory action on PDE III in the sinoatrial node (5) and may enhance IK and Ica. In this context, it is reasonable that milrinone shortened the action potential duration and increased Vm . The cyclic AMP level in papillary muscle was increased to the same extent by milrinone and toborinone at concentrations of 10-6 M and 3 x 10-5 M (4). Thus, toborinone may increase the cyclic AMP level as milrinone did in the sinoatrial node, although direct evidence remains to be obtained. Toborinone, however, did not shorten APD50 or increase Vma, in the present study. Furthermore, toborinone prolonged CL. This action is apparently opposite to those of other PDE III inhibitors (7) . Thus, other mechanisms may be involved in the change in action potential. Takase et al. (4, 8) reported that toborinone decreased IK in an isolated guinea pig ventricular muscle cell. In the present study, E-4031 depolarized MDP and decreased APA and Vmax concentration-dependently. These results are consistent with those obtained in the previous study (10) . Toborinone also depolarized MDP and decreased APA and Vmax. From this point of view, toborinone may act as an IK blocker rather than a PDE III inhibitor in the sinoatrial node. In the previous study, toborinone limited the increase in sinoatrial node activity (1, 4) . Since E-4031 prolonged CL in the present and previous studies (10) in the sinoatrial node preparation, one possible mechanism for the lack of positive chronotropism of toborinone may be in part due to its blocking action on IK. In other words, the positive chronotropic effect of toborinone by the elevation of cAMP level may be counteracted by the negative chronotropic effect due to the decrease in IK.
Not all of the changes in action potential parameters by toborinone, however, were similar to those by E-4031: Toborinone produced a decrease in OSP and virtually left APD50 unchanged, which is not the case with E-4031. Thus, toborinone seems to influence the membrane current in a complex manner. Further analyses are necessary to identify the current modulated by toborinone. 
